# CJC-1295 (with DAC)

> CJC-1295 with DAC is a modified growth hormone releasing hormone (GHRH) analog engineered with a Drug Affinity Complex that binds circulating albumin, dramatically extending its activity compared to unmodified GHRH. Early clinical research reported sustained elevations in growth hormone and IGF-1 over days to weeks following a single dose. It is widely used in research and community protocols as a long-acting alternative to shorter-acting GHRH analogs, often paired with a GHRP for a stronger combined effect. Its long clearance time means effects, and any side effects, can persist well after the last dose.

- URL: https://www.lifeconverted.com/peptides/cjc-1295-dac
- Also known as: CJC-1295, DAC:GRF
- Primary category: GH Releasing Hormones
- Effectiveness rank: #12 in Muscle & Performance; #2 in GH Releasing Hormones
- Evidence level: Moderate evidence
- Route: Subcutaneous (Injected subcutaneously; long half-life allows once- or twice-weekly dosing)
- Dose range: 1,000-2,000 mcg
- Dose tiers: low 1000 mcg; moderate 2000 mcg; high 2000 mcg
- Half-life: ~8 days
- Timing: ~30 min before bed, empty stomach
- Cycle: 12-16 weeks on, 4-8 weeks off (Long clearance means effects persist for weeks after stopping, so off-periods are extended accordingly)
- Storage: Store lyophilized powder refrigerated (2-8°C), protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within 2-4 weeks.

## Mechanism of action

The Drug Affinity Complex (DAC) covalently binds circulating albumin, protecting the attached GHRH(1-29) analog from rapid enzymatic degradation and greatly extending its half-life. This produces continuous, low-level stimulation of pituitary GHRH receptors, leading to a sustained rise in GH and IGF-1 rather than the discrete pulses seen with short-acting GHRH analogs.

## Reported benefits

- Sustained GH/IGF-1 elevation
- Improved recovery and sleep quality
- Supports lean mass over time
- Convenient low-frequency dosing

## Reported side effects

- Water retention
- Injection-site irritation
- Mild flushing or numbness after dosing
- Possible joint discomfort
- Fatigue at high doses

## Common protocols

- CJC-1295 DAC + Ipamorelin
- CJC-1295 DAC + GHRP-2

## Stacking notes

Commonly paired with a GHRP (such as Ipamorelin or GHRP-2) dosed separately to add pulsatile amplification on top of its sustained baseline elevation.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer